Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive symbols : Ions save search
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
Published: 2024-04-07 (Crawled : 16:20) - prnewswire.com
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
| Email alert
Add to watchlist
positive for results study
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
Published: 2024-03-25 (Crawled : 13:30) - biospace.com/
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: -0.14%
H: 3.12%
C: 2.93%
positive meeting cardiology
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
Published: 2024-03-13 (Crawled : 11:00) - prnewswire.com
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: 0.69%
H: 1.1%
C: -0.71%
ion224 positive treatment results study
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
Published: 2024-02-23 (Crawled : 12:00) - globenewswire.com
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: 0.25%
H: 2.95%
C: 2.88%
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 0.43%
H: 1.06%
C: -0.05%
qalsody first chmp genetic positive treat therapy
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema
Published: 2024-01-22 (Crawled : 15:30) - biospace.com/
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: 0.55%
H: 1.11%
C: -0.49%
positive topline results study
Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome
Published: 2023-11-11 (Crawled : 20:20) - prnewswire.com
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
| Email alert
Add to watchlist
ion582 positive update ongoing trial
Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema
Published: 2023-11-09 (Crawled : 21:00) - ionispharma.com
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: 0.53%
H: 0.38%
C: -2.52%
label positive extension results study
Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome
Published: 2023-09-26 (Crawled : 11:00) - prnewswire.com
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: 3.0%
H: 5.92%
C: 5.33%
positive topline results study
Ionis announces positive donidalorsen late-stage clinical progress in HAE
Published: 2023-06-01 (Crawled : 11:00) - prnewswire.com
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: 1.03%
H: 4.2%
C: 3.92%
positive
Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN
Published: 2023-03-27 (Crawled : 07:00) - prnewswire.com
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: 0.56%
H: 0.67%
C: -1.23%
positive topline eplontersen study
Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting
Published: 2022-11-13 (Crawled : 20:20) - prnewswire.com
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: 0.35%
H: 4.08%
C: 1.47%
label meeting extension positive study phase 2
Ionis announces positive data from GSK's Phase 2b clinical study of bepirovirsen
Published: 2022-11-08 (Crawled : 19:00) - biospace.com/
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: -0.22%
H: 2.77%
C: 1.76%
positive study phase 2b
Ionis presents positive Phase 2 data in patients with IgA Nephropathy at American Society of Nephrology's Kidney Week 2022
Published: 2022-11-07 (Crawled : 12:20) - prnewswire.com
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: 0.94%
H: 0.95%
C: -0.79%
nephropathy kidney week positive phase 2
Ionis announces positive results from fesomersen development program
Published: 2022-11-04 (Crawled : 12:00) - biospace.com/
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: -0.56%
H: 0.52%
C: -6.08%
program positive results
Ionis presents positive results from Phase 3 NEURO-TTRansform study at International Symposium on Amyloidosis
Published: 2022-09-07 (Crawled : 07:00) - prnewswire.com
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: 0.55%
H: 4.42%
C: 3.75%
symposium positive results international study
Ionis announces positive topline results from Phase 2b clinical study of fesomersen, a potential novel anti-thrombotic treatment
Published: 2022-07-28 (Crawled : 13:00) - biospace.com/
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: 1.92%
H: 0.1%
C: -0.99%
treatment topline potential positive results study phase 2b
Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™
Published: 2022-06-25 (Crawled : 16:20) - prnewswire.com
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
| Email alert
Add to watchlist
treatment hepatitis liver presentation positive international phase 2b chronic hepatitis b
Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session
Published: 2022-04-04 (Crawled : 05:00) - prnewswire.com
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: 0.1%
H: 0.41%
C: -0.54%
cardiology positive phase 2b
Ionis announces publication of positive Phase 2 data for donidalorsen in New England Journal of Medicine
Published: 2022-03-16 (Crawled : 00:00) - prnewswire.com
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: -0.15%
H: 2.62%
C: 2.45%
phase 2 pos positive
Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC
Published: 2021-07-26 (Crawled : 21:00) - prnewswire.com
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: 0.05%
H: 1.28%
C: -2.86%
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 0.04%
H: 0.73%
C: 0.57%
disease alzheimer treatment positive topline alzheimer’s alzheimer's disease alzheimer's
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.